[go: up one dir, main page]

DE60320088D1 - Neue komplexe methylierter cyclodextrine - Google Patents

Neue komplexe methylierter cyclodextrine

Info

Publication number
DE60320088D1
DE60320088D1 DE60320088T DE60320088T DE60320088D1 DE 60320088 D1 DE60320088 D1 DE 60320088D1 DE 60320088 T DE60320088 T DE 60320088T DE 60320088 T DE60320088 T DE 60320088T DE 60320088 D1 DE60320088 D1 DE 60320088D1
Authority
DE
Germany
Prior art keywords
cyclodextrine
methylated
cyclodextrin
new complex
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60320088T
Other languages
English (en)
Other versions
DE60320088T2 (de
Inventor
Tomi Jarvinen
Janne Mannila
Pekka Jarho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PEDIPHARM
Original Assignee
PEDIPHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PEDIPHARM filed Critical PEDIPHARM
Publication of DE60320088D1 publication Critical patent/DE60320088D1/de
Application granted granted Critical
Publication of DE60320088T2 publication Critical patent/DE60320088T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60320088T 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine Expired - Lifetime DE60320088T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20020333A FI20020333A0 (fi) 2002-02-20 2002-02-20 Metyloidun syklodekstriinin uudet kompleksit
FI20020333 2002-02-20
PCT/FI2003/000125 WO2003070774A1 (en) 2002-02-20 2003-02-20 Novel methylated cyclodextrin complexes

Publications (2)

Publication Number Publication Date
DE60320088D1 true DE60320088D1 (de) 2008-05-15
DE60320088T2 DE60320088T2 (de) 2009-06-04

Family

ID=8563271

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60320088T Expired - Lifetime DE60320088T2 (de) 2002-02-20 2003-02-20 Neue komplexe methylierter cyclodextrine

Country Status (10)

Country Link
US (1) US7423026B2 (de)
EP (1) EP1476472B1 (de)
AT (1) ATE391138T1 (de)
AU (1) AU2003205807B2 (de)
CA (1) CA2476833C (de)
DE (1) DE60320088T2 (de)
ES (1) ES2301780T3 (de)
FI (1) FI20020333A0 (de)
NZ (1) NZ535153A (de)
WO (1) WO2003070774A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI113340B (fi) * 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
AU2006262195A1 (en) * 2005-06-20 2007-01-04 Unimed Pharmaceuticals, Inc. Dronabinol treatment for migraines
LT2280687T (lt) 2008-03-26 2019-08-26 Stichting Sanammad Kramtomosios gumos kompozicijos, apimančios kanabinoidus
US8735374B2 (en) * 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
TR201815752T4 (tr) 2010-11-25 2018-11-21 Aop Orphan Pharmaceuticals Ag Nabilon ve rastomal metilen beta siklodekstrin içeren hızlı parçalanan bileşimler.
US9744128B2 (en) 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
EP3442521A4 (de) 2016-04-15 2020-01-01 SRE Wellness, Inc. Mit cannabis infundierte süssstoffe und elixire
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
JP2019511580A (ja) 2016-04-15 2019-04-25 エスアールイー ウェルネス インク.Sre Wellness Inc. 乳化剤を使用して大麻油を親水性にする方法及び関連するカンナビノイド組成物
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
WO2018058235A1 (en) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Sustained release cannabinoid formulations
US11097206B2 (en) 2016-12-09 2021-08-24 Orochem Technologies Inc. Method for producing purified steviol product using simulated moving bed chromatography
US10058531B1 (en) 2017-06-01 2018-08-28 Spartak LLC Dosage delivery film
SMT202200093T1 (it) 2017-09-28 2022-05-12 Zynerba Pharmaceuticals Inc Trattamento della sindrome dell’x fragile e dell'autismo con cannabidiolo
US11179340B2 (en) * 2017-12-29 2021-11-23 TGC Network LLC Cannabidiol dosage form
CA3088358A1 (en) * 2018-01-13 2019-07-18 Pure Green Pharmaceuticals, Inc. Transformation of cannabinol and terpene oils into water soluble dry powders for solid form sublingual delivery
US20200016091A1 (en) * 2018-07-16 2020-01-16 Orochem Technologies, Inc. Water-soluble cannabidiol
WO2020028897A1 (en) * 2018-08-03 2020-02-06 Lilu's Garden, Ltd. CONSTRUCT OF β-CYCLODEXTRIN AND CANNABINOID GUEST COMPLEX AND PROCESSES FOR PRODUCING A PASTE COMPRISING THE SAME
WO2020121260A1 (en) 2018-12-14 2020-06-18 Zynerba Pharmaceuticals, Inc. Treatment of 22q11.2 deletion syndrome with cannabidiol
US11660283B2 (en) * 2018-12-19 2023-05-30 Joyn Botanicals Ltd. Cannabinoid-containing composition
CN110123876A (zh) * 2019-05-30 2019-08-16 汉义生物科技(北京)有限公司 一种含有非精神活性大麻素的包合物及其制备方法
CN110204426B (zh) * 2019-07-02 2023-05-30 梁志全 一种水溶性cbd的制备方法及水溶性cbd
CN110433133A (zh) * 2019-08-19 2019-11-12 中国人民解放军军事科学院军事医学研究院 治疗创伤后应激障碍的大麻二酚鼻用制剂
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CN115003288A (zh) * 2019-10-21 2022-09-02 埃索拉特有限责任公司 超细化合物及其生产
EP3886837B1 (de) 2019-12-16 2024-02-14 Pisak, Mehmet Nevzat Zubereitungen enthaltend cannabinoiden mit erhöhter löslichkeit und bioverfügbarkeit
EP4090173A1 (de) * 2020-01-13 2022-11-23 Rrw B.V. Wässrige lösung einer lipophilen verbindung
EP3919046A1 (de) 2020-06-02 2021-12-08 Athenion AG Verfahren zur solubilisierung von natürlichen, endogenen und synthetischen cannabinoiden
EP4167979A1 (de) * 2020-06-19 2023-04-26 Cannovex BV Lungenformulierung mit cannabinoiden
CN116782885A (zh) * 2020-07-17 2023-09-19 康纳化学有限责任公司 固体δ9-四氢大麻酚(δ9-thc)组合物
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
WO2024097327A1 (en) * 2022-11-02 2024-05-10 Progressive Therapeutics, Inc. Cannabinoid formulations and use for treatment of emotional disorders and sexual dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
WO2003033025A2 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
FI113340B (fi) 2002-02-20 2004-04-15 Tomi Jaervinen Uudet luonnon syklodekstriinin kompleksit

Also Published As

Publication number Publication date
AU2003205807A1 (en) 2003-09-09
ATE391138T1 (de) 2008-04-15
CA2476833A1 (en) 2003-08-28
US20050090468A1 (en) 2005-04-28
EP1476472A1 (de) 2004-11-17
AU2003205807B2 (en) 2008-11-20
FI20020333A0 (fi) 2002-02-20
ES2301780T3 (es) 2008-07-01
US7423026B2 (en) 2008-09-09
WO2003070774A1 (en) 2003-08-28
EP1476472B1 (de) 2008-04-02
CA2476833C (en) 2011-02-01
DE60320088T2 (de) 2009-06-04
NZ535153A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
DE60320088D1 (de) Neue komplexe methylierter cyclodextrine
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
DE60135557D1 (de) Ajulemische Säure zur Krebsbehandlung
DE60139733D1 (de) Verschleißfeste Legierung auf Eisenbasis
BR0103356B1 (pt) compressor do tipo voluta.
NO20031473L (no) Prosessering av hydrokarbon gass
HRP20030472B1 (en) Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate
BR0308211A (pt) Cumarinas úteis como biomarcadores
NO20032788D0 (no) Modafinil-forbindelse og cyklodekstrinblandinger
DE60131927D1 (de) Heterosubstituierte taxan-c10-acetate als antitumormittel
ATE359279T1 (de) Moschus-geruchsstoffe
DE50202504D1 (de) Neue 4-aminofuropyrimidine und ihre verwendung
MXPA03008076A (es) Isoflavonas dimericas.
DK1204659T3 (da) Serotonerge benzofuraner
ATE505459T1 (de) Dibenzoäb,füazepin-derivate und ihre herstellung
ATE427970T1 (de) Verbesserte mikrogele und filme
DE60136430D1 (de) Heterosubstituierte c7-taxanacetate als antitumormittel
DE60134814D1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
DE60305964D1 (de) Pyridin-derivate verwendbar als riechstoffe
DE60133600D1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
DE60138853D1 (de) C10-taxanester als antitumormittel
TR200201192T1 (tr) Kanser terapi maddelerinin kuvvetlendirilmesine yönelik metod ve terkipler
HRP20031068B1 (en) Chloromethylation of thiophene
DE60213827D1 (de) Antikörper gegen Caspase-8, ihre Herstellung und Verwendung
DE60126764D1 (de) Glyoxal-phenol-kondensate mit gesteigerter fluoreszenz

Legal Events

Date Code Title Description
8364 No opposition during term of opposition